A Systems Toxicology-based Approach Reveals Biological Pathways Dysregulated by Prenatal Arsenic Exposure by Laine, Jessica E. & Fry, Rebecca C.
A Systems Toxicology Approach Reveals Biological Pathways 
Dysregulated by Prenatal Arsenic Exposure
Jessica E. Laine, MS and
Department of Epidemiology, Gillings School of Global Public Health, University of North 
Carolina, Chapel Hill, NC
Rebecca C. Fry, PhD
Department of Environmental Sciences and Engineering, Gillings School of Global Public Health, 
University of North Carolina, Chapel Hill, NC
Abstract
BACKGROUND—Prenatal exposure to inorganic arsenic (iAs) is associated with dysregulated 
gene and protein expression in the fetus, both evident at birth. Potential epigenetic mechanisms 
that underlie these changes include but are not limited to the methylation of cytosines (CpG).
OBJECTIVE—The aim of the present study was to compile datasets from studies on prenatal 
arsenic exposure to identify whether key genes, proteins, or both and their associated biological 
pathways are perturbed.
METHODS—We compiled datasets from 12 studies that analyzed the relationship between 
prenatal iAs exposure and fetal changes to the epigenome (5-methyl cytosine), transcriptome 
(mRNA expression), and/or proteome (protein expression changes).
FINDINGS—Across the 12 studies, a set of 845 unique genes was identified and found to enrich 
for their role in biological pathways, including those signaled by peroxisome proliferator-activated 
receptor, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, and the 
glucocorticoid receptor. Tumor necrosis factor was identified as a putative cellular regulator 
underlying most (n = 277) of the identified iAs-associated genes or proteins.
CONCLUSIONS—Given their common identification across numerous human cohorts and their 
known toxicologic role in disease, the identified genes and pathways may underlie altered disease 
susceptibility associated with prenatal exposure to iAs.
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INTRODUCTION
Inorganic arsenic (iAs) is ranked as the highest priority toxic agent by the Agency for Toxic 
Substances and Disease Registry.1 Exposure to iAs primarily occurs via contaminated 
drinking water. In addition to the detrimental health consequences associated with chronic 
exposure in adults, prenatal exposure to iAs is associated with adverse birth outcomes and 
susceptibility to diseases later in life.2 Specifically, prenatal iAs exposure has been 
associated with lower birth weight (BW), preterm birth, reduced height and head 
circumference, increased susceptibility to infection, including inflammation and infectious 
disease, and later life cancers.3
A single molecular mechanism is unlikely to underlie these diverse health outcomes, and 
many changes at the cellular level in circulating cord leukocytes in infants have been 
observed. For example, prenatal iAs exposure has been associated with changes to the fetal 
cord leukocyte epigenome, including changes to CpG methylation, altered transcription 
profiles, and changes in protein signaling.4-15 Thus, the pathophysiological consequences of 
prenatal iAs exposure are likely linked to complex dysregulation at the level of the 
epigenome, transcriptome, and proteome.
A growing body of literature supports the relationship between prenatal iAs exposure and 
changes to the fetal epigenome. With cord leukocytes as the primary target site of study, 
alterations in CpG methylation patterns in relation to prenatal iAs exposure have been 
observed in human population-based studies. Specifically, prenatal iAs exposure has been 
associated with global CpG methylation changes and 2 specific tumor suppressors in 
peripheral blood leukocytes in a cohort in Bangladesh.10 Gene-specific CpG methylation has 
been associated with iAs in Bangladesh and Thailand6,9 and genome-wide gene-specific 
changes observed in a pregnancy cohort in Mexico.14 Some alterations in CpG methylation 
profiles have been shown to be sex-specific: one study identified 3 CpG sites that altered 
significantly associated with iAs exposure in boys, but none in girls.6
Studies focusing on changes at the level of the fetal cord leukocyte transcriptome analyzing 
altered gene expression have identified many target genes that are altered in relationship to 
prenatal iAs exposure. Altered patterns of gene expression related to inflammatory signaling 
pathways were observed in cord blood leukocyte samples collected from newborns exposed 
prenatally to varying levels of iAs in Thailand8 and Mexico.13,14 Similarly, genes have been 
shown to be altered in cord blood and placental tissues from a pregnancy cohort in New 
Hampshire.7,11,12,15
In terms of protein expression studies, 2 studies have identified changes in protein 
abundance in relationship to prenatal iAs exposure. In a pregnancy cohort in Bangladesh, 18 
proteins were analyzed in cord blood for their associations with maternal urinary iAs and 3 
differentially expressed proteins were identified.4 Using the largest proteome assessment to 
date related to prenatal iAs exposure, a panel of 507 proteins was assessed in newborns 
exposed to iAs prenatally in Gómez Palacio, Mexico. A total of 111 proteins were found to 
be associated with prenatal iAs exposure, which are known to be regulated by tumor 
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necrosis factor (TNF) and are enriched in functionality related to immune/inflammatory 
response and cellular development/proliferation.5
Most of these aforementioned studies have examined the identified genes or proteins for 
biological pathways that are altered when exposed to prenatal iAs. However, the datasets 
have not been systematically evaluated to identify whether there are common genes or 
pathways that are dysregulated across multiple birth cohorts. Additionally, the genes altered 
at the level of the epigenome, transcriptome, and proteome have yet to be integrated across 
studies. Given that these genes and proteins are likely important contributors to 
environmental exposure-induced disease from prenatal iAs exposure, the identification of 
potential common biological pathways will aid in determining biomarkers of exposure or 
disease associated with iAs. We performed an analysis of datasets that assessed the 
molecular endpoints of epigenetic alterations (CpG methylation), gene expression, and 
protein expression in relationship to prenatal iAs exposure in human pregnancy cohort 
studies to identify key biological pathways that are perturbed as a result of prenatal exposure 
to iAs.
METHODS
Identifying Genes and Proteins Associated with iAs Exposure
To assess the relationship between prenatal iAs exposure from previous human cohort 
studies that evaluated CpG methylation, gene expression or protein expression changes, a 
literature review was performed in PubMed searching the terms, prenatal arsenic exposure 
plus one of the following terms, gene expression, epigenetics, DNA methylation, CpG 
methylation, and protein expression. From this search, 12 studies and their corresponding 
datasets were identified. Genes were represented if they were found to be significantly 
associated with prenatal iAs exposure as identified within the respective studies. Common 
gene identifiers were converted to an Entrez Gene number as an identifier for each gene and 
845 unique genes and proteins were identified across the 12 datasets.
Pathway Analyses
Genes or proteins were analyzed at a biological pathway level using 2 methods, namely 
Ingenuity Pathway Analysis (IPA; Ingenuity Systems®, Redwood City, CA, USA) and the 
Database for Annotation, Visualization, and Integrated Discovery (DAVID; 
david.ncifcrf.gov). Analyses were carried out for all genes (N = 845), as well as separately 
for genes that were identified as significantly associated with prenatal iAs levels from all 
gene expression studies (n = 731), those that were identified from studies examining CpG 
methylation (n = 61), and those that encode proteins from studies that assessed protein 
expression (n = 114). To perform these analyses, genes identified from the individual studies 
were analyzed using their Entrez gene number. Significant enrichment of canonical 
pathways was assessed using IPA and the Kyoto Encyclopedia of Genes and Genomes 
pathways were identified using DAVID. Benjamini-Hochberg-corrected P values were 
reported for all canonical pathways in IPA. The P value determined by DAVID is an absolute 
enrichment P value determined by a modified Fischer’s Exact Test.16 Pathways were 
prioritized based on the overlap between IPA and DAVID and top hits between them. The 
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enrichment of cellular regulators for all proteins and genes (N = 845) was carried out using 
IPA.
RESULTS
Generation of a Cross-study Database of Gene/Proteins Modified in Relation to Prenatal 
iAs Exposure
Twelve studies that assessed epigenetic, genomic, and proteomic alterations in cord 
leukocytes or placental tissue of newborns exposed prenatally to iAs exposure were 
identified. Of these studies, 5 investigated CpG methylation, 6 focused on gene expression, 
and 2 investigated protein expression (Table 1). One of the studies examined the relationship 
between changes to CpG methylation with concomitant changes in gene expression.14
The following studies investigated changes to CpG methylation in response to prenatal iAs 
exposure: Broberg et al. carried out a genome-wide methylation analysis of cord blood 
leukocytes from 127 infants from a pregnancy cohort in Matlab, Bangladesh.6 
Intarasunanont et al. conducted a global CpG methylation and TP53-specific analysis of 
cord blood leukocytes from 71 newborns with prenatal iAs exposure from southern 
Thailand.9 Kile et al. analyzed global CpG methylation and 2 gene-specific tumor 
suppressors of cord blood leukocytes in response to prenatal iAs in 113 mothere–-baby pairs 
from Sirajdikhan Upazila, Bangladesh.10 Koestler et al. performed a genome-wide gene-
specific CpG methylation study of cord blood leukocytes 134 infants nested in the NHBCS 
(New Hampshire Birth Cohort Study).11 Rojas et al. performed a genome-wide gene-
specific study of cord leukocytes in a cohort of 40 mother–baby pairs from the BEAR 
(Biomarkers of Exposure to ARsenic) pregnancy cohort in Gómez Palacio, Mexico. Unlike 
previous studies, genes identified in the BEAR cohort (N = 54) were altered both at the gene 
expression level and in CpG methylation status.14
The following studies were identified that investigated gene expression profiles in response 
to prenatal iAs exposure: Fei et al. investigated the expression of 9 predicted iAs-associated 
genes in placental tissue from 133 pregnant women from New Hampshire7; Fry et al. 
identified 447 differentially expressed genes from a genome-wide analysis in fetal cord 
blood leukocytes of 32 infants in Thailand8; Nadeau et al. analyzed immune-specific gene 
expression in placental tissues from 70 women who were exposed to iAs in New 
Hampshire.12 Additionally, Winterbottom et al. assessed placenta gene-specific expression 
in 133 placental tissues for associations with iAs exposure and fetal growth.15 Rager et al. 
identified 334 differentially expressed mRNAs from a genome-wide analysis in cord blood 
leukocytes in the BEAR pregnancy cohort of 40 mother–baby pairs.13
Two of the 12 studies analyzed protein expression associated with prenatal iAs exposure. 
Ahmed et al. performed a targeted analysis of 18 inflammation-associated cytokines in cord 
blood leukocytes in a cohort of 130 pregnant women from Bangladesh.4 Bailey et al. 
investigated iAs-associated changes to the prenatal proteome with prenatal iAs exposure in 
the cord blood serum of 50 newborns from the BEAR cohort in Gómez Palacio, Mexico.5
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Assessing Gene/Protein Expression Trends Across Datasets
Across the 12 studies that assessed in the present study, 845 genes were identified as being 
associated with prenatal iAs exposure (Supplementary Table 1). Of these genes, 731 were 
from studies that assessed gene expression, 61 were identified from studies of CpG 
methylation, and 114 from studies that assessed protein expression. Additionally, 61 genes 
were identified to be altered for 2 molecular endpoints where 54 genes had altered levels of 
gene expression as well as altered levels of CpG methylation in relation to prenatal iAs 
exposure, and 7 genes had altered gene expression levels as well as protein expression levels 
(Fig. 1; Supplementary Table 2). Additionally, when examining the overlap of genes and 
proteins across studies independent of the molecular endpoint assessed, 67 genes were 
identified in at least 2 studies (Supplementary Table 2). Of these, 17 were common to 
studies from different pregnancy cohorts (Table 1). Specifically these genes were interleukin 
(IL)-1 beta (IL1β), IL-8 (IL8), chemokine (C-C motif) receptor 2 (CCR2), chemokine (C-C 
motif) receptor 3 (CCR3), chemokine (C-X-C motif) ligand 1 (melanoma growth-
stimulating activity alpha) (CXCL), chemokine (C-X-C motif) receptor 4 (CXCR4), 
epiregulin (EREG), chemokine (C-X-C motif) ligand 16 (CXCL16), ferritin, heavy 
polypeptide 1; ferritin, heavy polypeptide-like 16; similar to ferritin, heavy polypeptide 1; 
ferritin, heavy polypeptide-like 3 pseudogene (FTH1), muscleblind-like 2 (MBNL2), nuclear 
factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (NFKBIA), 
triggering receptor expressed on myeloid cells 1 (TREM1), casein kinase 1, delta 
(CSNK1D), HLA complex group 27 (HCG27), tribbles homolog 1 (TRIB1), GLI family 
zinc finger 2 (GLI2), and porcupine homolog (PORCN) (Table 2).
Identified Enriched Biological Pathways
Pathway analysis was performed for all genes within the database (N = 845), and separately 
for genes derived from studies that focused on a specific molecular endpoint (ie, CpG 
methylation; n = 61 genes), gene expression (n = 731 genes), or protein expression (n = 113 
genes/proteins). Among the set of 845 genes identified to be associated with prenatal iAs 
exposure, there was an enrichment for pathways associated with known transcription factors 
including peroxisome proliferator-activated receptor (PPAR), NF-κB, transforming growth 
factor (TGF)-β, glucocorticoid receptor, among others (Supplementary Table 3).
The genes identified with differential CpG methylation (n = 61), were enriched for pathways 
known to play a role in cell cycle and apoptosis including Myc-mediated apoptosis, G1/S 
checkpoint regulation, tumor protein p53 (Supplementary Table 3). The genes with altered 
expression in relationship to prenatal iAs (n = 731) were enriched for the following immune 
and inflammatory response pathways: toll-like receptor (TLR), glucocorticoid receptor, 
inducible nitric oxide synthase (iNOS), and IL-6 (Supplementary Table 3). Of the 113 genes 
with altered protein expression, there was an enrichment for the growth factors that play a 
role in inflammation including TGF-β, bone morphogenetic protein (BMP) signaling 
pathway, and fibroblast growth factors (FGF; Supplementary Table 3).
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In Silico Identification of Regulatory Molecules Reveals the TNF Pathway as a Master 
Regulator
Analysis was performed on the 845 genes and proteins to identify key cellular regulators 
predicted to control gene and protein expression. These include signaling molecules, 
transcription factors, or both. This analysis identified TNF as a key cellular regulator of the 
genes/proteins across all studies (Fig. 2; Supplementary Table 4). These proteins include 
those belonging to the following pathways: ILB, interferon (IFN)-γ, jun proto-oncogene 
(JUN), NF-κB complex, NF-κBIA, NF-κB1, prostaglandin E2, v-rel avian 
reticuloendotheliosis viral oncogene homolog A (RELA), SMAD family member 4 
(SMAD4), signal transducers and activators of transcription-1 (STAT1), signal transducers 
and activators of transcription-3 (STAT3), and TGFB1. Interestingly, the 17 genes that were 
common across cohorts were also enriched for TNF as a common regulator (P = 1.06 × 
10−9).
DISCUSSION
Prenatal exposure to iAs is associated with detrimental health outcomes at birth as well as 
later life disease. In the hunt for the molecular basis for these outcomes, prior research has 
focused on examining gene/pathway disruption in fetal cord leukocytes or in placental 
tissues associated with prenatal iAs exposure. Previous studies have demonstrated that 
prenatal exposure to iAs is associated with alterations to the fetal epigenome including 
altered levels of CpG methylation, as well as changes in gene expression, and altered protein 
expression in cord leukocytes or placental tissue. However, it is currently not known whether 
there are common pathways targeted by iAs exposure across these studies. In the present 
study, we used a systems toxicologic approach to assess the relationship between prenatal 
iAs exposure and several molecular endpoints. We generated a database from 12 studies 
examining prenatal iAs-associated changes to the epigenome (CpG methylation), the 
transcriptome (mRNA expression), or proteome (protein expression changes). A set of 845 
genes that were enriched for pathways regulated by TNF were identified as key regulators of 
prenatal iAs exposure and disease. Interestingly, given the vastly different geographic 
locations of the pregnancy cohorts from which these data are derived, 17 genes were 
common across cohorts independent of the molecular endpoint under study and known to be 
regulated by TNF. Given the known relationship between prenatal exposure to iAs and 
several adverse birth outcomes, early-life health outcomes, and disease later in life, the 
identification of common pathways could provide insight into disease etiology.
Across all 845 genes identified here, transcription factor regulator-associated pathways and 
immune/inflammation-response pathways were identified. These included PPAR, NF-κB, 
gluco-corticoid receptor, and TLRs. Many of these pathways have been previously 
associated with exposure to iAs, iAs-associated diseases, or both. For example, it has been 
suggested that decreased expression of PPAR-γ and altered glucocorticoid receptor-
mediated transcription are pathologic events associated with iAs-induced diabetes.17 The 
finding in the present study of NF-κB as a dysregulated pathway associated with prenatal 
iAs exposure was previously reported.8 This is relevant because many cellular effects of iAs 
have been shown to be mediated through arsenic’s ability to modulate NF-κB activity.18-21 
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Toll-like receptors, identified here, are known to play an important role in innate immune 
signaling. Supporting our findings, these receptors have been shown to have altered 
expression in animal studies where a subset of genes involved in innate immune response, 
including IL-1 and TLR, were identified to have altered expression within lungs of mice 
exposed to iAs.22 Taken together, these results highlight the importance of PPAR, NF-κB, 
TLRs, that likely play an important role in determining how prenatal iAs exposure 
influences cellular signaling at the pathway level.
Interestingly, the top cellular regulator for all identified genes and proteins and for the set of 
17 genes common to multiple pregnancy cohorts was TNF, which plays a critical role in 
inflammation and cellular growth/development-related signaling.23 Our results are 
consistent with previous findings that proteomic shifts from prenatal iAs exposure is 
associated with TNF-receptor superfamily members.5,10 Additionally, an animal study of 
iAs exposed mice suggest that TNF is involved in inflammatory reactions in the liver and 
subsequent tissue injury and fibrosis.24 Furthermore, TNF has been implicated to be 
important in iAs-associated disease, where previous studies of iAs-exposed individuals have 
identified polymorphisms within the TNF promoter are associated with increased levels of 
TNF and a higher incidence of skin lesions, respiratory diseases, and conjunctivitis.25 These 
results, coupled with evidence from prior studies, demonstrate that TNF may be an 
important signaling molecule mediating the relationship between prenatal iAs exposure and 
iAs-associated disease.
The search for genes that are altered in different ways in the cell, either through CpG 
methylation or gene expression or protein expression modification, resulted in the 
identification of 61 common genes and proteins. This finding highlights the diverse ways 
that iAs can affect gene regulation with targeted CpG methylation influencing both the 
expression of genes and proteins. Interestingly, we identified 17 genes that were altered in 
response to prenatal iAs exposure and were commonly derived from multiple studies of 
different cohorts. Many of these genes play a role in inflammation, including interleukins, 
chemokines, FTH1, NFKBIA, TREM1, and TRIB1. As these cohorts are geographically 
diverse based in Bangladesh, Thailand, Mexico, and the United States, the fact that there are 
commonalities at the gene and pathway level highlight the conservation in the response of 
the fetus to prenatal exposure to iAs.
The findings here are significant because they provide a hypothesis for specific biological 
mechanisms by which prenatal exposure to iAs can disrupt cell signaling observed across 
numerous prenatal cohort studies. However, this study is not without limitations. The 
methodologies of the studies used to compile the database differed, including statistical 
methodologies for gene set identification that could affect the genes included in the current 
analysis. Nevertheless, to our knowledge, this is the first study to perform an integrated 
assessment of changes to fetal cell signaling and integration of epigenetic, transcriptomic, 
and proteomic datasets.
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The present study used a systems toxicologic approach to identify a set of genes from 
multiple studies that examined molecular markers of prenatal iAs exposure. Interestingly, 
many genes were altered across studies, even those focused on different molecular endpoints 
with the largest overlap between studies of gene expression and CpG methylation. However, 
there was some additional overlap between gene and protein expression studies. 
Additionally, a unique set of genes that is common across multiple pregnancy cohorts across 
different geographic locations suggested a conserved biological response to prenatal iAs 
exposure. TNF was identified as a potentially important regulator underlying most of the 
identified genes and proteins. The results from this study may inform future research on the 
molecular mechanisms of the relationship between prenatal iAs exposure and disease.
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The heatmap depicts genes (N = 845) identified as changed in relationship to prenatal iAs in 
studies focusing on the epigenome (CpG methylation), the transcriptome (gene expression), 
and the proteome (protein expression) representing 12 studies. Red shading indicates that the 
gene was significantly associated with prenatal iAs exposure. Gray shading indicates that the 
gene was not significantly associated with prenatal iAs exposure. *The 54 genes that had 
altered levels of gene expression as well as altered levels of CpG methylation in relation to 
prenatal iAs exposure. †The 7 genes that had altered gene expression levels as well as 
protein expression levels.
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Top upstream regulator, tumor necrosis factor (TNF), identified as enriched among the iAs-
associated genes (N = 845).
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Table 1
Summary of Studies Included for Analysis (N = 12)
Study (PMID) Participants (n) Geographic Location Molecular Marker Tissue
Ahmed et al., 2011 
(20940111)
130 Matlab, Bangladesh Protein expression Placenta/cord blood
Bailey et al., 2014 
(24675094)
50 Gómez Palacio, Mexico Protein expression Cord blood
Broberg et al., 2014 
(24965135)
127 Matlab, Bangladesh CpG methylation Cord blood
Fei et al., 2013 
(23866971)
133 New Hampshire, United States Gene expression Placenta
Fry et al., 2007 
(18039032)
32 Thailand Gene expression Cord blood
Intarasunanont et al., 2012 
(22551203)
71 Thailand CpG methylation Cord blood
Kile et al., 2012 
(22466225)
113 Sirajdikhan Upazila, Bangladesh CpG methylation Cord blood
Koestler et al., 2013 
(23757598)
134 New Hampshire, United States CpG methylation Cord blood
Nadeau et al., 2014 
(25229165)
70 New Hampshire, United States Gene expression Placenta
Rager et al., 2014 
(24327377)
40 Gómez Palacio, Mexico Gene expression Cord blood
Rojas et al., 2014 
(25304211)
38 Gómez Palacio, Mexico CpG methylation/Gene expression Cord blood
Winterbottom et al., 2015 
(26288817)
133 New Hampshire, United States Gene expression Placenta
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Table 2
Genes/Proteins (n = 17) Associated with Prenatal iAs Exposure Common to Different Study Cohorts
Gene Official Gene Name Source
IL1B Interleukin 1, beta (Fry 2007)*, (Nadeau 2014)*
IL8 Interleukin 8 (Fry 2007)*, (Ahmed 2011)†
CCR2 Chemokine (C-C motif) receptor 2 (Fry 2007)*, (Bailey 2014)†
CCR3 Chemokine (C-C motif) receptor 3 (Fry 2007)*, (Bailey 2014)†
CXCL1 Chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating 
activity, alpha)
(Fry 2007)*, (Bailey 2014)†
CXCR4 Chemokine (C-X-C motif) receptor 4 (Fry 2007)*, (Bailey 2014)†
EREG Epiregulin (Fry 2007)*, (Bailey 2014)†
CXCL16 Chemokine (C-X-C motif) ligand 16 (Fry 2007)*, (Rager 2014)*, (Bailey 2014)†
FTH1 Ferritin, heavy polypeptide 1; ferritin, heavy polypeptide-like 16; similar 
to ferritin, heavy polypeptide 1; ferritin, heavy polypeptide-like 3 
pseudogene
(Fry 2007)*, (Rager 2014)*
MBNL2 Muscleblind-like 2 (Drosophila) (Fry 2007)*, (Rager 2014)*
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha
(Fry 2007)*, (Rager 2014)*
TREM1 Triggering receptor expressed on myeloid cells 1 (Fry 2007)*, (Rager 2014)*
CSNK1D Casein kinase 1, delta (Fry 2007)*, (Rager 2014)*, (Rojas 2014)*,‡
HCG27 HLA complex group 27 (Fry 2007)*, (Rager 2014)*, (Rojas 2014)*, ‡
TRIB1 Tribbles homolog 1 (Drosophila) (Fry 2007)*, (Rager 2014)*, (Rojas 2014)*, ‡
GLI2 GLI family zinc finger 2 (Rager 2014)*, (Rojas 2014)*,‡, (Winterbottom 
2015)*
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